Recognition

Since 2011, I have got the great honor to work as a fellow for the EORTC Headquarters for the Quality of Life Department under the leadership of Dr. Andrew Bottomley. At the start of my fellowship at the EORTC, I had limited idea of what quality of life in clinical research was and what was the role of a statistician in this area. Most of my knowledge in quality of life in cancer clinical trial came from the trainings I received at the EORTC Headquarters either during clinical presentation, but also from external seminars I was allowed to attend in different organizations or congresses (ASCO, ISOQOL, ESMO, ISPOR,...).

The completion of this thesis is a unique opportunity to thank Prof. dr. M.J.B Taphoorn, my promotor, for his kind support and encouragements throughout this thesis.

I am extremely grateful to my co-promotors drs. Linda Dirven and J.C. Reijneveld. Dr. Linda, thanks to our passionate discussions and precious advice for the analysis, interpretation and writing of each chapter of this thesis, I could improve my knowledge in the interpretation of high-quality quality of life data. Dr. Jaap, for all the support, valuable feedback and interpretations especially in quality of life in high-grade glioma patients. No words can explain my gratitude and support over these years.

I am also in debt to Dr. Andrew Bottomley, Assistant Director of the EORTC Quality of Life Department, for his support, encouragement and trust. You helped me to better understand the state of quality of life research and clinical management of cancer. You also truly encouraged me to pursue my research in quality of life and helped improving the analysis, interpretation and writing of the main message of each publication. You followed all the steps of this thesis with enthusiasm and support. Without you this thesis would have not been possible.

I want to thank my colleagues from EORTC HQ, especially Corneel Coens who provided me with his precious advices to improve the statistical methodological interpretation and writing of the prognostic modelling publications.
I am very grateful to my mother for her continuous support and encouragement, to brothers and sisters who have always been there for me. To my dad who did not have the chance to enjoy the fruit of his labor. To my wife for bearing with me during the writing of this thesis. And to my friends and family for their love and care.
Role of the funding source

The data of the trials that were used in this study were supported by: grants from the Belgian Cancer Foundation and USA grant No 5U10 CA011488-39 through 5U10 CA011488-40 from National Cancer Institute (Bethesda, MD), the Cancer Research Fund of the European Organization for Research and Treatment of Cancer, Pfizer Global Partnership Foundation, the King Baudouin Foundation, La Fondation Contre le Cancer and National Cancer Institute.
Acknowledgements

We thank the Canadian Cancer Trials Group (CCTG) and patients who contributed or consented to these CCTG trials; MA16, MA8, CX2, HN1, HN2, MY7, SC15, BR8, SC8, SC19, CO10, CO7, CO9, BR10, BR9, OV10, and SC11. We would like to thank the EORTC Lung Cancer Cooperative Group, especially the principal investigator Prof Dr Egbert F Smit, and the EORTC Head & Neck Cancer Group, especially the principal investigator Prof. Dr. Jan B. Vermorken. We also thank the EORTC Gastro-Intestinal Tract Cancer Cooperative Group and the other investigators and all patients who participated in the following EORTC trials, EORTC 08975, EORTC 26951, EORTC 40986, EORTC 40952. We thank the neurologists, neurosurgeons, and radiation oncologists from Amsterdam University Medical Centers, locations VUmc and AMC, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Slotervaart Hospital (Amsterdam), Leiden University Medical Center (Leiden); Haaglanden Medical Center, HAGA Hospital (The Hague); Erasmus University Medical Center (Rotterdam); Elisabeth-TweeSteden Hospital (Tilburg); Maastricht University Medical Center (Maastricht); Hospital De Wever (Heerlen); University Medical Center Utrecht (Utrecht); Sint Antonius Hospital (Nieuwegein); Radboud University Medical Center (Nijmegen); and Groningen University Medical Center, Martini Hospital (Groningen) for permission to include their patient-proxy dyads in the study and the Dutch Cancer Society. Furthermore, we would like to thank Sheila Scott-Sanderson and Cheryl Whittaker for editorial help.
List of publications


Curriculum Vitae

Divine Ediebah is born on April 13, 1982 in Bamenda, North West Province, Cameroon. After graduating from high school education at the Government Bilingual High School (Cameroon) he started studying Biochemistry at the University of Yaoundé 1 (Yaoundé, Cameroon). He graduated in 2004 with mention “Very Good”. In 2006, he started the Master of Science in Applied Statistics at the University of Hasselt and graduated in 2007. In 2007, he started another Master of Science in Biostatistics at the University of Hasselt and graduated in 2008. Between 2008–2011 he was a statistician at 4Clinics (Waterloo, Belgium) working as a consultant with GSK Biologicals, Rixensart. Between 2011–2014 he joined the EORTC Headquarter in the Quality of Life Department as a research fellow under the leadership of Dr Andrew Bottomley. He made several contributions in quality of life (ISPOR, ISOQOL) and cancer (ESMO–ECCO, ASCO) conferences.

In April 2014, he joined Abbott vascular International as a statistician until present.

In 2015, after discussion with Prof. Dr. M.J.B. Taphoorn, he registered as a PhD student at the Vrije Universiteit Amsterdam for the present research. EORTC and Abbott offered him the possibility to write his thesis in conjunction with his regular work at Abbott.